{
}
UBS has maintained a Buy rating for Sarepta Therapeutics with a price target of $188, despite a recent patient death linked to its gene therapy Elevidys, which has caused the stock to drop over 26%. Analyst Eliana Merle views the market reaction as exaggerated and emphasizes the ongoing demand for Elevidys, the only approved treatment for Duchenne muscular dystrophy. While some analysts express caution regarding safety and sales forecasts, others remain optimistic about the drug's potential and future revenue growth.
Sarepta Therapeutics' shares saw volatility following a patient's death linked to its gene therapy, Elevidys, yet UBS analyst Eliana Merle maintained a Buy rating with a target of USD 188, viewing the market's reaction as an overreaction. Despite the incident, demand for Elevidys remains strong, and revenue growth is robust at 53% year-over-year. Analysts' responses vary, with some expressing caution while others uphold positive outlooks for the company's future performance.
Regenxbio Inc showcased its leadership in gene therapy at the UBS Virtual CNS Day 2025, highlighting three late-stage programs: RGX-121, RGX-202, and RGX-314. The company has completed the BLA submission for RGX-121, with potential approval by the end of 2025, while RGX-202 aims for accelerated approval with pivotal enrollment expected to finish in the latter half of the year. Additionally, RGX-314's partnership with AbbVie could yield $500 million in milestone payments, focusing on diabetic retinopathy and wet AMD.
REGENXBIO is optimistic about achieving accelerated approval for its gene therapy targeting micro dystrophin, particularly in younger patients where existing treatments are lacking. The company emphasizes the importance of safety and differentiation, noting their approach to mitigate complement activation risks and the promising functional data observed in clinical trials. Ongoing discussions with the FDA have reinforced their confidence in the approval pathway, with plans to enroll approximately 30 patients by the end of the year.
REGENXBIO Inc.
Companies
| Symbol | RGNX |
| Name | REGENXBIO Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MD |
| City | Rockville |
| Zipcode | 20850 |
| Website | http://www.regenxbio.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
Regenxbio showcases gene therapy advancements at UBS Virtual CNS Day 2025
13:13 18.03.2025
advancements in gene therapy for muscular dystrophy show promising clinical results
13:12 18.03.2025
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Supply Chain Management
Global Trade Developments
Retail and Consumer Goods
Industry Mergers & Acquisitions
Government Economic Policies
Private Equity Deals
CEO Changes
Workplace Trends
Stock Market Updates
Emerging Startups
Corporate Social Responsibility
Funding Rounds & Investments
Consumer Protection Regulations
Fintech Startups
AI Innovations
Global Trade Policies
Anti-Money Laundering (AML) Regulations
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Amazon.com, Inc.
JD.com, Inc.
Tesla, Inc.
Toyota Motor Corp
Honda Motor Co., Ltd.
Microsoft Corporation
Samsung Securities Co.,Ltd.
Meituan
Tesmec S.p.A.
Emirates NBD Bank PJSC
Boeing Co
The Goldman Sachs Group, Inc.
Foxconn Technology Co., Ltd.
HP Inc.
KiloEx USD
Opec
XIAOMI-W
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
Euro
Japanese Yen
British Pound Sterling
Offshore Chinese Yuan
Indonesian Rupiah
Nigerian Naira
Nicaraguan Córdoba
New Taiwan Dollar
Qatari Riyal
Mexican Peso
Pakistani Rupee
Saudi Riyal
Malaysian Ringgit
Vietnamese Đồng
South Korean Won
Singapore Dollar
Macanese Pataca
People: